Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Rare Tumour × atezolizumab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 117 Carcinoma, Hepatocellular 67 Neoplasms 46 Breast Neoplasms 46 Small Cell Lung Carcinoma 42 Lung Neoplasms 37 Triple Negative Breast Neoplasms 36 Melanoma 34 Colorectal Neoplasms 34 Carcinoma, Transitional Cell 34 Urinary Bladder Neoplasms 29 Neoplasm Metastasis 28 Carcinoma, Renal Cell 24 Ovarian Neoplasms 19 Stomach Neoplasms 15 Head and Neck Neoplasms 15 Squamous Cell Carcinoma of Head and Neck 14 Uterine Cervical Neoplasms 13 Liver Neoplasms 12 Prostatic Neoplasms 11 Recurrence 10 Solid Tumors 9 Lymphoma 9 Glioblastoma 9 Sarcoma 8 Pancreatic Neoplasms 8 Esophageal Neoplasms 8 Mesothelioma, Malignant 7 Kidney Neoplasms 7 Endometrial Neoplasms 7

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡